About this episode

Emily Conley discusses the development of small molecule therapies for a rare kidney disease.

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

More episodes of The Long Run with Luke Timmerman

• Ep200: Richard Pops Reflects on a 35-Year Career in Biotech · May 5, 2026 · 1h 14m
• Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery · April 7, 2026 · 1h 17m
• Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature · March 31, 2026 · 1h 17m
• Ep196: Otello Stampacchia on Europe's Biotech Crisis · March 17, 2026 · 1h 3m
• Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases · March 3, 2026 · 1h 6m
• Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery · February 17, 2026 · 1h 9m

Explore listener stats, chart rankings, contacts and more on the The Long Run with Luke Timmerman podcast page.